. "158102" . "Hecogov\u00E1, Jana" . . . . "[D9307DD7D8D1]" . . "1" . "RIV/00064211:_____/12:#0000211!RIV14-MZ0-00064211" . . . . "The study describes the case of a patient with a clinical and histopathological diagnosis of pemphigus vulgaris accompanied by severe side-effects of combined immunosuppressive therapy, who achieved a remission of the disease with adalimumab. Pemphigus vulgaris is a chronic blistering disease of the skin and mucous membranes. Before corticosteroids were introduced, mortality was high. Corticosteroids are currently used as first-line therapy. To reduce the dose of corticosteroids, therapeutic combinations with corticosteroid-sparing immunosuppressive agents are used. The therapy brings a number of complications due to its side effects. To achieve a remission of the disease by treating our patient with combined immunosuppressives, we administered adalimumab and achieved a very good clinical response." . "Pemphigus vulgaris treated with adalimumab: case study" . "25" . . . "CZ - \u010Cesk\u00E1 republika" . "4"^^ . "I" . "adalimumab; biological therapy; corticosteroids; pemphigus vulgaris; infliximab"@en . "3"^^ . "1396-0296" . "Pemphigus vulgaris treated with adalimumab: case study"@en . . . . "Voj\u00E1\u010Dkov\u00E1, Nad\u011B\u017Eda" . . . "4"^^ . . "Pemphigus vulgaris treated with adalimumab: case study" . "000304088300011" . . "10.1111/j.1529-8019.2012.01433.x" . . "RIV/00064211:_____/12:#0000211" . "Pemphigus vulgaris treated with adalimumab: case study"@en . . "Fialov\u00E1, Jorga" . "The study describes the case of a patient with a clinical and histopathological diagnosis of pemphigus vulgaris accompanied by severe side-effects of combined immunosuppressive therapy, who achieved a remission of the disease with adalimumab. Pemphigus vulgaris is a chronic blistering disease of the skin and mucous membranes. Before corticosteroids were introduced, mortality was high. Corticosteroids are currently used as first-line therapy. To reduce the dose of corticosteroids, therapeutic combinations with corticosteroid-sparing immunosuppressive agents are used. The therapy brings a number of complications due to its side effects. To achieve a remission of the disease by treating our patient with combined immunosuppressives, we administered adalimumab and achieved a very good clinical response."@en . "Va\u0148ousov\u00E1, Daniela" . "Dermatologic Therapy" . .